Explore 3 Stock Ideas & Industry Insights Download Free Report

888-969-2592
Shopping Cart 0
countryflagCA
Login

Home CompaniesMaxCyte Inc

MaxCyte Inc

Healthcare Medical Devices
PortfolioPortfolio WatchlistWatchlist
Company price
1.26 USD -0.05 ( 3.82%)
Last update at 2026-11-06T21:00:00Z
VOLUME
876060
Market Cap
489.39M

Momentum Score

…

MaxCyte, Inc., a life sciences company, discovers, develops, and commercializes next-generation cell therapies in the United States and internationally. Its products include ExPERT ATx, a static electroporation instrument for small to medium scale transfection; ExPERT STx, a flow electroporation for protein production and drug development, as well as expression of therapeutic targets for cell-based assays; ExPERT GTx, a flow electroporation for large scale transfection in therapeutic applications; and ExPERT VLx for very large volume cell-engineering. The company also provides disposable processing assemblies (PAs) to process and electroporate cells; and accessories supporting PAs, such as electroporation buffer solution and software protocols. It licenses and sells its instruments and technology; and sells its consumables to developers of cell therapies, as well as to pharmaceutical and biotechnology companies for use in drug discovery and development, and bio-manufacturing. MaxCyte, Inc. was incorporated in 1998 and is headquartered in Rockville, Maryland.

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Day Price Range
1.24
Low
1.36
High
52 Week Price Range
2.45
Low
5.54
High

Momentum Score

…
Loading momentum score…

A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.

Score - Rating
>= 1 - Low / > 1 but < 2 - Below Average / > 2 but < 3 - Average / > 3 but < 4 - Above Average / > 4 - High

Key Metrics*

Previous Close
1.31
Dividend Yield
-
Revenue TTM
44.05M
Revenue Per Share
0.42
Gross Profit TTM
39.16M
Debt / Equity
0.08
ROE
-15.42%
Net Debt
-27.76M
ROCE
-10.93%
Diluted EPS TTM
-0.35

Key Financials*

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Income before tax -23.57M -19.08M -11.82M -12.89M -8.87M
Net income -19.78M -20.13M -12.64M -13.58M -8.87M
Selling general administrative 25.83M 18.68M 8.39M 6.09M 5.28M
Selling and marketing expenses 18.65M 13.00M 8.33M 7.85M 6.72M
Gross profit 39.16M 30.25M 23.40M 19.12M 14.83M
Reconciled depreciation 2.70M 1.42M 1.05M 0.61M 0.34M
Ebit -27.36M -18.19M -11.06M -12.42M -8.25M
Ebitda -20.75M -16.61M -9.94M -11.60M -7.91M
Depreciation and amortization 6.61M 1.57M 1.11M 0.82M 0.34M
Non operating income net other 3.79M -0.89M - - -
Operating income -27.36M -18.19M -11.06M -12.42M -8.42M
Other operating expenses 71.62M 52.08M 37.23M 34.04M 25.09M
Interest expense 0.13M 1.04M 0.83M 0.68M 0.61M
Tax provision 0.00M 0.00M - - -
Interest income 3.92M 0.15M 0.07M 0.21M 0.17M
Net interest income 3.79M -0.89M -0.76M -0.47M -0.44M
Income tax expense -3.79M 1.04M 0.83M 0.68M 0.17M
Total revenue 44.26M 33.89M 26.17M 21.62M 16.67M
Total operating expenses 66.52M 48.44M 34.46M 31.54M 23.25M
Cost of revenue 5.10M 3.65M 2.77M 2.50M 1.84M
Total other income expense net 3.79M -0.89M -0.76M -0.47M -0.44M
Net income from continuing ops -23.57M -19.08M -11.82M -12.89M -8.87M
Net income applicable to common shares -23.57M -19.08M -11.82M -12.89M -8.87M
Breakdown 2023-12-31 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Type yearly yearly yearly yearly yearly
Date 2023-12-31 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Total assets 268.27M 286.65M 284.12M 51.78M 29.99M
Other current assets 3.90M 2.78M 3.31M 1.00M 0.80M
Total liab 36.11M 32.69M 21.22M 18.55M 16.38M
Total stockholder equity 232.17M 253.97M 262.90M 33.23M 13.60M
Other current liab 11.27M 8.03M 6.52M 5.21M 3.55M
Common stock 1.04M 1.02M 1.01M 0.77M 0.57M
Capital stock 1.04M 1.02M 1.01M 0.77M 0.57M
Retained earnings -175.80M -137.88M -114.30M -95.22M -83.41M
Other liab - 1.32M 0.45M 0.65M 0.34M
Other assets - 0.81M 0.32M 0.03M -
Cash 46.51M 11.06M 47.78M 18.76M 15.21M
Total current liabilities 17.86M 15.43M 15.62M 11.61M 9.34M
Current deferred revenue 5.07M 6.71M 6.75M 4.84M 3.19M
Net debt -27.76M 5.03M -42.10M -11.79M -8.00M
Short term debt 0.77M 0.16M 0.53M 0.67M 0.51M
Short long term debt total 18.74M 16.09M 5.68M 6.97M 7.21M
Other stockholder equity 406.93M 390.82M 376.19M 127.67M 96.43M
Property plant equipment - 23.72M 13.37M 6.49M 5.53M
Total current assets 190.19M 252.27M 270.43M 45.25M 24.45M
Long term investments 42.94M - - - -
Net tangible assets - 253.97M 262.90M 33.23M 13.60M
Short term investments 121.78M 216.27M 207.26M 16.01M 1.50M
Net receivables 5.78M 13.57M 6.88M 5.17M 3.24M
Long term debt - - - 4.92M 4.90M
Inventory 12.23M 8.58M 5.20M 4.32M 3.70M
Accounts payable 0.74M 0.53M 1.82M 0.89M 2.09M
Common stock total equity - 1.02M 1.01M 0.77M 0.57M
Retained earnings total equity - -137.88M -114.30M - -
Non currrent assets other 0.39M 0.81M 0.32M 0.03M -
Non current assets total 78.08M 34.39M 13.69M 6.53M 5.53M
Capital lease obligations 18.74M 16.09M 5.68M 2.05M 2.32M
Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Investments -6.35M -191.18M -14.51M 1.73M -3.12M
Change to liabilities 0.69M 3.99M 2.04M 1.96M 0.01M
Total cashflows from investing activities -24.82M -195.01M -16.58M 0.45M -3.83M
Net borrowings - -4.99M -0.06M -0.15M -0.00M
Total cash from financing activities 2.89M 234.72M 28.90M 12.31M 0.23M
Change to operating activities 7.16M -2.53M -0.20M -0.05M -0.23M
Net income -23.57M -19.08M -11.82M -12.89M -8.87M
Change in cash -36.72M 29.03M 3.54M 3.96M -14.09M
Begin period cash flow 47.78M 18.76M 15.21M 11.25M 25.34M
End period cash flow 11.06M 47.78M 18.76M 15.21M 11.25M
Total cash from operating activities -14.78M -10.68M -8.78M -8.80M -10.49M
Issuance of capital stock 0.00M 236.08M 28.57M 12.33M 0.00M
Depreciation 2.70M 1.42M 1.05M 0.61M 0.34M
Other cashflows from investing activities - 0.00M - - -
Change to inventory -3.49M -1.41M -0.89M -1.89M -1.29M
Change to account receivables -6.69M -1.71M -1.81M 1.59M -1.95M
Sale purchase of stock 2.89M 239.71M - - -
Other cashflows from financing activities -2885.61M 3.63M 1.84M 5.09M 0.28M
Change to netincome 11.89M 8.62M 2.84M 1.87M 1.50M
Capital expenditures 18.48M 3.83M 2.07M 1.27M 0.71M
Change receivables -4.78M -1.71M - - -
Cash flows other operating 4.45M -2.40M - - -
Cash and cash equivalents changes -36.72M 29.03M - - -
Change in working capital -3.21M -1.64M -0.86M 1.61M -3.46M
Stock based compensation 11.75M 7.96M 2.47M 1.75M 1.32M
Other non cash items -2.45M 0.06M 0.10M 0.08M 0.07M
Free cash flow -33.26M -14.51M -10.85M -10.07M -11.20M

Peer Comparison*

Sector: Healthcare Industry: Medical Devices

Stock Name
Change
(USD)
Price
(USD)
Trailing
PE (x)
Forward
PE (x)
Price Sales
TTM (x)
Price to Book Value (x)
Enterprise Value
to Revenue (x)
Enterprise Value
to EBITDA (x)
MXCT
MaxCyte Inc		 -0.05
3.82%		 1.26 - - 11.25 2.19 5.62 -11.07
ABT
Abbott Laboratories		 -0.03
0.03%		 109.93 25.97 17.24 3.57 3.20 3.81 16.75
MDT
Medtronic PLC		 -3.04
2.90%		 101.80 26.60 15.87 3.35 2.08 3.90 14.12
SYK
Stryker Corporation		 -9.21
2.75%		 325.87 29.23 16.86 4.18 4.51 4.63 17.16
SEMHF
Siemens Healthineers AG		 -2.15
4.12%		 49.85 39.57 21.32 3.01 3.29 2.95 16.92

Profile*

MaxCyte Inc

MaxCyte, Inc., a life sciences company, discovers, develops, and commercializes next-generation cell therapies in the United States and internationally. Its products include ExPERT ATx, a static electroporation instrument for small to medium scale transfection; ExPERT STx, a flow electroporation for protein production and drug development, as well as expression of therapeutic targets for cell-based assays; ExPERT GTx, a flow electroporation for large scale transfection in therapeutic applications; and ExPERT VLx for very large volume cell-engineering. The company also provides disposable processing assemblies (PAs) to process and electroporate cells; and accessories supporting PAs, such as electroporation buffer solution and software protocols. It licenses and sells its instruments and technology; and sells its consumables to developers of cell therapies, as well as to pharmaceutical and biotechnology companies for use in drug discovery and development, and bio-manufacturing. MaxCyte, Inc. was incorporated in 1998 and is headquartered in Rockville, Maryland.

9713 Key West Avenue, Rockville, MD, United States, 20850

301 944 1700

https://www.maxcyte.com

143

Name Title Year Born
Mr. Douglas Arthur Doerfler Founder, Pres, CEO & Exec. Director 1956
Mr. Ronald Evan Holtz CPA, Ph.D. Chief Financial Officer 1958
Dr. J. Stark Thompson Ph.D. Consultant 1942
Dr. Cenk Sumen Chief Scientific Officer 1973
Mr. Sean Menarguez Director of Investor Relations NA
Mr. Maher Masoud Exec. VP, Gen. Counsel & Sec. 1975
Mr. Thomas Michael Ross Exec. VP of Global Sales 1961
Dr. James Brady Ph.D. Sr. VP of Technical Applications & Customer Support NA
Dr. Sarah Haecker Meeks Ph.D. Sr. VP of Bus. Devel. NA
Mr. James Lovgren Sr. VP of Global Marketing NA

Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.

Kalkine

3 Mining Stock
Ideas Report

Download a free report with stock ideas and industry insights for general information.

Download Free Report Now → sector image

Top Stocks by Market Cap*

ITH
CAD 2.15
+27.68%
HG
CAD 4.11
+19.13%
PPTA
CAD 27.74
+17.99%
UCU
CAD 2.10
+17.32%
GAU
CAD 3.49
+16.72%
TSU
CAD 29.67
-29.71%
PXT
CAD 19.73
-16.91%
LAS-A
CAD 230.50
-9.25%
IFP
CAD 13.50
-8.35%
NFI
CAD 24.01
-7.80%

Equity Sectors*

  • Basic Materials

    +3.74%

  • Communication Services

    +0.56%

  • Consumer Cyclical

    -0.34%

  • Consumer Defensive

    +0.11%

  • Energy

    +1.33%

  • Financial Services

    -0.26%

  • Healthcare

    +2.54%

  • Industrials

    -0.11%

  • Real Estate

    -0.23%

  • Technology

    +1.91%

  • Utilities

    +1.05%

Note: Daily price change (%) by sector excluding stocks with +/-90% daily price change. Companies above $500 million market capitalization are considered.

Support

Hi! How can we help you today?

Loading…